Manipulation of Lipid Metabolism During Normothermic Machine Perfusion: Effect of Defatting Therapies on Donor Liver Functional Recovery

Abstract

Strategies to increase the use of steatotic donor livers are required to tackle the mortality on the transplant waiting list. We aimed to test the efficacy of pharmacological enhancement of the lipid metabolism of human livers during ex situ normothermic machine perfusion to promote defatting and improve the functional recovery of the organs. Because of steatosis, 10 livers were discarded and were allocated either to a defatting group that had the perfusate supplemented with a combination of drugs to enhance lipid metabolism or to a control group that received perfusion fluid with vehicle only. Steatosis was assessed using tissue homogenate and histological analyses. Markers for lipid oxidation and solubilization, oxidative injury, inflammation, and biliary function were evaluated by enzyme‐linked immunosorbent assay, immunohistochemistry, and in‐gel protein detection. Treatment reduced tissue triglycerides by 38% and macrovesicular steatosis by 40% over 6 hours. This effect was driven by increased solubility of the triglycerides ( P = 0.04), and mitochondrial oxidation as assessed by increased ketogenesis ( P = 0.008) and adenosine triphosphate synthesis ( P = 0.01) were associated with increased levels of the enzymes acyl‐coenzyme A oxidase 1, carnitine palmitoyltransferase 1A, and acetyl‐coenzyme A synthetase. Concomitantly, defatted livers exhibited enhanced metabolic functional parameters such as urea production ( P = 0.03), lower vascular resistance, lower release of alanine aminotransferase ( P = 0.049), and higher bile production ( P = 0.008) with a higher bile pH ( P = 0.03). The treatment down‐regulated the expression of markers for oxidative injury as well as activation of immune cells (CD14; CD11b) and reduced the release of inflammatory cytokines in the perfusate (tumor necrosis factor α; interleukin 1β). In conclusion, pharmacological enhancement of intracellular lipid metabolism during normothermic machine perfusion decreased the lipid content of human livers within 6 hours. It also improved the intracellular metabolic support to the organs, leading to successful functional recovery and decreased expression of markers of reperfusion injury.

References 27

1. 1.

   Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007;132:2191‐2207.

   Not in our library10.1053/j.gastro.2007.03.055

2. 2.

   Chu MJ, Dare AJ, Phillips AR, Bartlett AS. Donor hepatic steatosis and outcome after liver transplantation: a systematic review. J Gastrointest Surg 2015;19:1713‐1724.

   Not in our library10.1007/s11605-015-2832-1

3. 3.

   Liu Q, Izamis ML, Xu H, Berendsen T, Yarmush M, Uygun K. Strategies to rescue steatotic livers before transplantation in clinical and experimental studies. World J Gastroenterol 2013;19:4638‐4650.

   Not in our library10.3748/wjg.v19.i29.4638

4. 4.

   Garcia Urena MA, Colina Ruiz‐Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, et al. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998;22:837‐844.

   Not in our library10.1007/s002689900479

5. 5.

   Liu Q, Nassar A, Buccini L, Iuppa G, Soliman B, Pezzati D, et al. Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion. Liver Transpl 2018;24:233‐245.

   Not in our library10.1002/lt.24972

6. 6.

   Nagrath D, Xu H, Tanimura Y, Zuo R, Berthiaume F, Avila M, et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng 2009;11:274‐283.

   Not in our library10.1016/j.ymben.2009.05.005

7. 7.

   Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, Friend PJ. Hepatic steatosis and normothermic perfusion‐preliminary experiments in a porcine model. Transplantation 2011;92:289‐295.

   Not in our library10.1097/tp.0b013e318223d817

8. 8.

   Taba Taba Vakili S, Kailar R, Rahman K, Nezami BG, Mwangi SM, Anania FA, Srinivasan S. Glial cell line‐derived neurotrophic factor‐induced mice liver defatting: a novel strategy to enable transplantation of steatotic livers. Liver Transpl 2016;22:459‐467.

   Not in our library10.1002/lt.24385

9. 9.

   Oniscu GC. Liver retrieval and bench surgery In: Oniscu GC, Forsythe JL, Fung J, eds. Abdominal Organ Retrieval and Transplantation Bench Surgery. Hoboken, NJ: John Wiley & Sons; 2013:73‐90.

   Not in our library

10. 10.

    Boteon YL, Wallace L, Boteon APCS, Mirza DF, Mergental H, Bhogal RH, Afford S. An effective protocol for pharmacological defatting of primary human hepatocytes which is non‐toxic to cholangiocytes or intrahepatic endothelial cells. PLoS ONE 2018;13:e0201419.

    Not in our library10.1371/journal.pone.0201419

11. 11.

    Boteon YL, Boteon APCS, Attard J, Mergental H, Mirza DF, Bhogal RH, Afford SC. Ex situ machine perfusion as a tool to recondition steatotic donor livers: troublesome features of fatty livers and the role of defatting therapies. A systematic review. Am J Transplant 2018;18:2384‐2399.

    Not in our library10.1111/ajt.14992

12. 12.

    Laing RW, Mergental H, Yap C, Kirkham A, Whilku M, Barton D, et al. Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open‐label, non‐randomised, prospective, single‐arm trial. BMJ Open 2017;7:e017733.

    Not in our library10.1136/bmjopen-2017-017733

13. 13.

    Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 2012;5:187‐194.

    Not in our library

14. 14.

    Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989;47:903‐905.

    Not in our library10.1097/00007890-198905000-00034

15. 15.

    Transplant NBa. Annual Report on Liver Transplantation 2015/2016. 2016 https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/1314/organ_specific_report_liver_2016.pdf. Accessed March 3, 2019.

    Not in our library

16. 16.

    Mergental H, Perera MT, Laing RW, Muiesan P, Isaac JR, Smith A, et al. Transplantation of declined liver allografts following normothermic ex‐situ evaluation. Am J Transplant 2016;16:3235‐3245.

    Not in our library10.1111/ajt.13875

17. 17.
    Observations on the ex situ perfusion of livers for transplantation · 2018

    No notice
18. 18.

    Nativ NI, Yarmush G, So A, Barminko J, Maguire TJ, Schloss R, et al. Elevated sensitivity of macrosteatotic hepatocytes to hypoxia/reoxygenation stress is reversed by a novel defatting protocol. Liver Transpl 2014;20:1000‐1011.

    Not in our library10.1002/lt.23905

19. 19.

    Yarmush G, Santos L, Yarmush J, Koundinyan S, Saleem M, Nativ NI, et al. Metabolic flux distribution during defatting of steatotic human hepatoma (HepG2) cells. Metabolites 2016;6.

    Not in our library10.3390/metabo6010001

20. 20.

    Villar‐Palasi C, Guinovart JJ. The role of glucose 6‐phosphate in the control of glycogen synthase. FASEB J 1997;11:544‐558.

    Not in our library

21. 21.

    Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012;23:351‐363.

    Not in our library10.1016/j.tem.2012.05.001

22. 22.

    Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferator‐activated receptors and the control of inflammation. Curr Drug Targets Inflamm Allergy 2002;1:243‐248.

    Not in our library10.2174/1568010023344616

23. 23.

    Chan EY, Olson LC, Kisthard JA, Perkins JD, Bakthavatsalam R, Halldorson JB, et al. Ischemic cholangiopathy following liver transplantation from donation after cardiac death donors. Liver Transpl 2008;14:604‐610.

    Not in our library10.1002/lt.21361

24. 24.

    Nativ NI, Maguire TJ, Yarmush G, Brasaemle DL, Henry SD, Guarrera JV, et al. Liver defatting: an alternative approach to enable steatotic liver transplantation. Am J Transplant 2012;12:3176‐3183.

    Not in our library10.1111/j.1600-6143.2012.04288.x

25. 25.

    Nativ NI, Yarmush G, Chen A, Dong D, Henry SD, Guarrera JV, et al. Rat hepatocyte culture model of macrosteatosis: effect of macrosteatosis induction and reversal on viability and liver‐specific function. J Hepatol 2013;59:1307‐1314.

    Not in our library10.1016/j.jhep.2013.07.019

26. 26.

    Reiling J, Lockwood DSR, Simpson AH, Campbell CM, Bridle KR, Santrampurwala N, et al. Urea production during normothermic machine perfusion: price of success? Liver Transpl 2015;21:700‐703.

    Not in our library10.1002/lt.24094

27. 27.

    Banan B, Watson R, Xu M, Lin Y, Chapman W. Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers. Liver Transpl 2016;22:979‐993.

    Not in our library10.1002/lt.24451

Cited by papers we hold 1

• The Immunological Basis of Liver Allograft Rejection · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.